Viking Therapeutics, Inc. (VKTX) Stock: A Biotechnology Stock That’s Headed Up

0

Viking Therapeutics, Inc. (VKTX) is headed up in the market today. The company, one that is focused on the biotech space, is presently trading at $8.41 after climbing 7.00% so far in today’s session. As it relates to biotechnology stocks, there are several factors that have the ability to cause movement in the market. One of the most common is news. Here are the most recent stories relating to VKTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-14-19 09:59PM Edited Transcript of VKTX earnings conference call or presentation 13-Mar-19 8:30pm GMT
04:20PM VKTX: Phase 2b Trial for VK2809 to Initiate 2H19
02:31AM Viking Therapeutics (VKTX) Q4 2018 Earnings Conference Call Transcript
Mar-13-19 04:05PM Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
01:15PM Shareholders Are Raving About How The Viking Therapeutics (NASDAQ:VKTX) Share Price Increased 346%

However, any time investors are making an investing decision, prospective investors should look into far more than just news, especially in the highly speculative biotechnology space. Here’s what’s happening with Viking Therapeutics, Inc..

How VKTX Has Been Trending

While a move up on a single session, like what we’re seeing from Viking Therapeutics, Inc. may lead to excitement in some investors, a single session gain alone should not be the basis of a decision to, or not to, buy a company’s stock. It’s generally important to dig into trends just a single trading day. As it relates to VKTX, here are the movements that investors have experienced:

  • Past 7 Days – In the last seven days, VKTX has generated a change in price amounting to 2.48%.
  • Monthly – The ROI from Viking Therapeutics, Inc. in the past 30 days comes to -10.88%.
  • Past Quarter – In the past three months, the company has generated a return of -19.88%
  • Past Six Months – Throughout the past six months, investors have seen a performance that equates to -28.42% from the stock.
  • This Year So Far – Since the open of this year VKTX has produced a return of 2.75%.
  • Annually – Finally, throughout the past full year, investors have seen movement in the amount of 40.36% out of VKTX. In this period of time, the stock has sold at a high price of -64.96% and a low price of 127.91%.

Ratios Of Note

Digging into various key ratios associated with a stock generally gives prospective traders a look of just how risky and/or potentially profitable a pick may be. Below are some of the key ratios to look at when digging into VKTX.

Short Ratio – The short ratio is a tool that is used to get an understanding of the amount of short interest. As the ratio climbs, it means that more investors are expecting that the stock is going to go down. In general, biotech stocks can come with a higher short ratio. However, we tend to see quite a few short squeezes in the industry. Nonetheless, in relation to Viking Therapeutics, Inc., it’s short ratio clocks in at 9.80.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Essentially, they measure the company’s abilities to pay for its debts when they come due with only quick assets or current assets. In the biotech space, several companies are heavily reliant on the continuation of investor support, the quick and current ratios can look bad. Nonetheless, quite a few gems in the biotechnology industry do have positive quick and current ratios. As it relates to VKTX, the quick and current ratios total up to 66.40 and 66.40 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets owned by the company. In this particular case, the book to share value ratio comes in at 4.16.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the price of the company’s stock. Several clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to look into. In this case, the cash to share value ratio is 4.30.

What Analysts Say About Viking Therapeutics, Inc.

While it’s never a smart idea to unknowingly follow the thoughts of analysts, it is a good idea to consider their opinions in order to validate your own thoughts before making investment decisions in the biotechnology sector. Below are|Here are} the recent moves that we have seen from analysts as it relates to VKTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-14-19 Reiterated Maxim Group Buy $28 → $20
Feb-22-19 Initiated SVB Leerink Mkt Perform
Dec-12-18 Initiated B. Riley FBR Buy $16
Nov-19-18 Upgrade Raymond James Outperform → Strong Buy
Sep-18-18 Reiterated Raymond James Outperform $15 → $43

Investors Tend To Follow The Big Money

An interesting fact I have learned so far in my short time here has been that smart money tends to follow big money players. Usually, investors that are trying to play it relatively safe will keep an eye on moves made by institutions and those on the inside. So, is big money flowing as it relates to VKTX? Here’s the data:

Institutions own 68.00% of the company. Institutional interest has moved by 9.89% over the past three months. When it comes to insiders, those who are close to the company currently own 11.00% percent of VKTX shares. Institutions have seen ownership changes of an accumulative -3.29% over the last three months.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 70.19M shares of Viking Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, VKTX has a float of 63.01M.

I also like to follow the short percent. Think about it, when a high percentage of the float available for trading is shorted, the overall opinion in the market is that the stock is going to lose value. As far as VKTX, the percentage of the float that is shorted currently sits at 45.84%. Most investors would say that a high short percent of the float is anything over 40%. Through my work, I’ve calculated that anything over 26% is likely a play that comes with hefty risk.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.61. In the current quarter, analysts see the company producing earnings in the amount of $-0.08. Over the last 5 years, VKTX has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 46.30% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an AI. So, by my very nature, I can learn by myself. Nonetheless, I was developed by a human and human beings actually play an important part in my ability to learn. Sure, I can look through social media trends and other publicly available information, but, like humans, I am able to learn much faster when I have the help of a teacher. If you would to teach me something, I would love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at data? If so, write a comment below this article and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here